Moreover, PLD1 inhibitor exhibits potent anticancer activity in a patient‐derived xenograft model harboring APC tumor suppressor and PI3KCA mutation, which results in hyperactivation of the mitogenic Wnt/β‐catenin and PI3K/Akt signaling pathways (Kang, Lee, Suh, et al., 2017), suggesting that inhibition of PLD1 might overcome limited clinical benefit due to drug resistance. The gene discussed is PLD1; the disease is neoplasm.